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Subclinical Hypothyroidism has Little Influences on Muscle Mass 
or Strength in Elderly People
Sarcopenia, the age-related decline in muscle mass, affects the muscle strength and muscle 
quality, and these changes decrease functional capacity. The prevalence of thyroid 
dysfunction increases with age, and changes in thyroid hormone level lead to 
neuromuscular deficits. We investigated the effects of subclinical hypothyroidism on the 
muscle mass, strength or quality in elderly people. One thousand one hundred eighteen 
subjects aged ≥65 yr were randomly selected from a local population and classified into a 
euthyroid (280 men and 358 women), subclinically hypothyroid (61 men and 75 women), 
or overtly hypothyroid (7 men and 16 women) group. Although women with subclinical 
hypothyroidism had a higher prevalence of sarcopenia, defined according to the ratio of 
appendicular skeletal muscle mass to the square of height, muscle mass, strength or quality 
did not differ in relation to thyroid status in men or in women. Multivariate analysis 
including age, diabetes, hypertension, acute coronary event, alcohol, smoking, presence of 
pain, physical activity score, and lipid profile, showed that thyroid-stimulating hormone 
level was not associated with muscle mass, strength or quality. In conclusion, subclinical 
hypothyroidism has little influences on muscle mass, strength or quality, and may not be 
associated with sarcopenia.
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INTRODUCTION
Sarcopenia is the age-related decline in lean body mass (1). The 
prevalence of sarcopenia is about 3-24%, increases with age (2, 
3), and is >50% in people older than 80 yr (4, 5). The decline in 
muscle mass causes a decline in muscle strength and quality 
(5-7), which lead to frailty and loss of independence in elderly 
people. Muscle strength is closely related to the absolute quan-
tity of muscle mass, which also declines with aging (8). 
  Skeletal muscle is a target organ for thyroid hormones, and 
neuromuscular deficits are well-recognized in hypothyroidism 
(9, 10). Hyperthyroidism can affect limb muscle mass and 
strength. In people with overt and subclinical hyperthyroidism, 
knee flexor and extensor muscle strength and midthigh muscle 
cross-sectional area are significantly lower compared with val-
ues in euthyroid people (11). However, the association between 
muscle mass or strength and subclinical hypothyroidism has 
not been reported. Thyroid dysfunction is common in elderly 
people, and the prevalence of thyroid dysfunction, especially 
subclinical hypothyroidism, increases with age (12, 13). 
  In this study, we investigated the prevalence of sarcopenia 
and the effects of subclinical hypothyroidism on muscle mass, 
strength, and quality in healthy men and women aged 65 yr or 
older. 
MATERIALS AND METHODS
Subjects
This study was performed as a part of the Korean Longitudinal 
Study on Health and Aging (KLoSHA) (14). A simple random 
sample (n=1,118) was drawn from the roster of 61,730 Korean 
elderly individuals aged ≥65 yr who were residents in Seong-
nam, Korea, on August 1, 2005. We excluded 217 subjects who 
had known thyroid disease, regardless of whether they were 
treated with medication, or had undetermined thyroid function.
  We also excluded 96 subjects who had known stroke to ex-
clude its effects on physical disability. Among the 805 subjects 
enrolled, we selected 797 subjects based on their results on a Moon MK, et al.  •  Subclinical Hypothyroidism and Sarcopenia in Elderly People
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thyroid function test: 638 had normal thyroid function, 136 were 
subclinically hypothyroid (SCH), and 23 were overtly hypothy-
roid (OVH). Measures of thyroid function included the concen-
trations of serum thyroid-stimulating hormone (TSH) and free 
thyroxine (fT4), which were measured using a commercial im-
munoradiometric assay (Abbott, North Chicago, IL, USA). Eu-
thyroidism was defined as concentrations of TSH and fT4 with-
in the normal reference ranges of 0.4–4.1 mU/L and 0.7–1.8 ng/
dL, respectively. Subclinical hypothyroidism and overt hypo-
thyroidism were defined as normal and low fT4 concentration, 
respectively, and elevated TSH were defined as a concentration 
>4.1 mU/L. All participants were informed fully about the study, 
and either they or a legal guardian provided written informed 
consent. The Institutional Review Board of the Seoul National 
University Bundang Hospital approved the study protocol (B-
0508/023-003).
Questionnaires and anthropometric measurements
During the initial visit, all subjects completed a standardized 
questionnaire designed to evaluate their medical history, which 
included questions about their history of diabetes mellitus, hy-
pertension, hyperlipidemia, stroke, acute coronary event, and 
thyroid dysfunction. Current medication profile, smoking and 
alcohol history, and the presence of body pain were acquired 
systematically. Height, body weight, waist circumference, and 
blood pressure were measured. Body mass index was then cal-
culated by determining the ratio between weight and height 
squared (in kg/m
2). Hypertension was defined as a self-reported 
history of hypertension, use of antihypertensive medication, or 
blood pressure ≥140/90 mmHg.
  Physical activity, performance, and disability were assessed 
using the physical activity score (PAS) (15), performance-ori-
ented mobility assessment (POMA) (16), short physical perfor-
mance battery (SPPB) (17), Activity-specific Balance Confidence 
(ABC) scale (18), the presence of knee pain, and Western On-
tario and McMaster Universities (WOMAC) (19). The quality of 
life was evaluated using the short form 36 (SF36) questionnaire 
(20). 
Laboratory measurement
The plasma fasting and 2-hr postload glucose concentration af-
ter ingestion of 75 g oral glucose were measured by the glucose 
oxidase method using a YSI 2300 STAT glucose analyzer (Yellow 
Spring Instrument Co., Yellow Springs, Ohio, USA). Total cho-
lesterol, triglyceride, low density lipoprotein cholesterol, high 
density lipoprotein cholesterol, blood urea nitrogen, and serum 
creatinine level were measured enzymatically using an autoan-
alyzer (Hitachi 747, Hitachi, Ltd., Tokyo, Japan) on the same day 
of the study after the subject had fasted for a minimum of 12-hr. 
Diabetes was defined as a self-reported history of diabetes or if 
the subject received antidiabetic treatment, had a fasting plas-
ma glucose concentration ≥7.0 mM/L, or a postload 2-hr glucose 
concentration ≥11.1 mM/L (21). Metabolic syndrome was de-
fined by the criteria of the National Cholesterol Education Pro-
gram Adult Treatment Panel III definition using the Asia-Pacific 
abdominal obesity criteria (waist circumference ≥90 cm in men 
and ≥80 cm in women) (22).
Muscle mass measurement by computed tomography (CT)
The abdominal adipose tissue areas (visceral fat and subcuta-
neous fat areas in cm
2) and midthigh areas were quantified by a 
single scout scan with a CT (Somatom Sensation 16, Siemens, 
Erlangen, Germany). A 5-mm CT slice scan was acquired at the 
umbilical level to measure the total abdominal and visceral fat 
areas, and adipose tissue attenuation was then determined by 
measuring the mean value of all pixels within the range of –190 
to –30 Hounsfield units. The scan of the midthigh muscle level 
was taken at the midthigh, defined as the midpoint from the in-
guinal crease to the proximal pole of the patella.
Muscle mass measurement by dual energy X-ray 
absorptiometry (DXA)
Appendicular skeletal muscle mass (ASM) was measured by 
DXA (Lunar Corporation, Madison, WI, USA). We used 2 defini-
tions for sarcopenia. One was the ASM divided by height squared 
(ASM/Ht
2, expressed as kg/m
2) proposed by Baumgartner et al. 
(4). The other was ASM as a percentage of body (ASM/Wt ex-
pressed as a percentage), which was modified from the study of 
Janssen et al. (23). Sarcopenia was defined as <1 standard devi-
ation (SD) below the sex-specific mean for a young reference 
group. The cutoff point for sarcopenia was 7.09 kg/m
2 in men 
and 5.27 kg/m
2 in women using ASM/Ht
2. For ASM/Wt, the 
cutoff was 29.9% in men and 25.1% in women. The sex-specific 
young reference group included 32 healthy men (mean age, 
28.4±3.1 yr) and 38 women (mean age, 26.3±2.6 yr). All scans 
were obtained by one certified technician. Total and leg lean 
body mass, total fat mass, and total body bone mineral content 
were measured in kilograms.
Muscle strength and muscle quality measurements
Maximum isometric knee extension and flexion strength were 
measured as peak force (in kilograms) on a digital force gauge 
fixed to a stand. Muscle strength was measured during knee ex-
tension and flexion using an isokinetic dynamometer (Biodex 
Isokinetic Tester, Biodex Medical Systems, Inc., Shirley, NY, USA). 
Force was measured in both legs unless contraindicated by pain 
or a history of joint replacement. We obtained total work from 
the sum of the total area under all the torque curves in the 20 
test repetitions. Muscle quality was assessed by the ratio of peak 
torque or total work to the leg lean mass obtained by DXA (5) or 
the midthigh muscle area obtained by CT.Moon MK, et al.  •  Subclinical Hypothyroidism and Sarcopenia in Elderly People
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Statistical analysis
The data are presented as means±SD or numbers (percentages) 
separately for men and women. Student’s t test and a chi-square 
test were used to compare variables between SCH subjects and 
euthyroid subjects. Analysis of variance (ANOVA) was used to 
compare the 3 groups (euthyroid, SCH, and OVH). P<0.05 was 
considered significant. Binary logistic and multiple regression 
analyses were used to examine the relationships between thy-
roid status, sarcopenia, muscle mass, strength, and quality.
RESULTS
Anthropometric and laboratory characteristics of the 
subjects
The men included 280 euthyroid, 61 SCH, and 7 OVH subjects. 
Their mean fT4 and TSH concentrations differed significantly 
between groups (fT4, 1.26±0.25 in euthyroid, 1.24±0.24 in SCH, 
0.63±0.07 in OVH subjects; P<0.001; TSH, 2.25±0.90 in euthy-
roid, 6.17±1.98 in SCH, and 16.91±18.34 in OVH subjects; P< 
0.001). The men’s anthropometric and metabolic characteristics 
including body mass index, waist circumference, blood pres-
sure, glucose and lipid profiles, and muscle enzyme levels did 
not differ between groups. Use of alcohol, smoking, past medi-
cal history of diabetes, hypertension, or an acute coronary event, 
and the prevalence of metabolic syndrome also did not differ 
between groups (data not shown).
  The women showed similar characteristics as the men; there 
were 358 euthyroid, 75 SCH, and 15 OVH subjects. Their mean 
fT4 levels were 1.20±0.25 in euthyroid, 1.14±0.27 in SCH, and 
0.59±0.12 in OVH (P<0.001). The TSH levels were 2.31±0.91 in 
euthyroid, 6.60±3.03 in SCH, and 26.29±45.64 in OVH subjects 
(P<0.001). Only the mean age of the OVH group (82.4±8.2 yr) 
was significantly higher than in the other groups (euthyroid, 
76.1±9.2; SCH, 74.6±8.0) (P=0.008). All other parameters did 
not differ significantly between groups (data not shown).
The effects of subclinical hypothyroidism on muscle mass 
or sarcopenia
Muscle mass measured by DXA or CT did not differ between 
euthyroid subjects and SCH subjects in men or women (Table 
1). Muscle mass tended to be lower in OVH subjects (men, 44.9 
±4.8 kg; women, 33.0±4.6 kg) than in euthyroid subjects (men, 
47.6±5.0 kg; women, 34.7±6.5 kg) and SCH subjects (men, 47.3± 
4.8 kg; women, 33.3±3.0 kg), but these differences were not sig-
nificant, possibly because of the small number of OVH subjects. 
Fat mass, fat area by CT, and midthigh muscle area by CT did not 
differ between groups. The prevalence of sarcopenia defined as 
ASM/Ht
2 was 34.9% in men and 9.6% in women; the prevalence 
Table 1. Muscle mass and prevalence of sarcopenia according to the thyroid functional status
Parameters
Male Female
Euthyroid (n=181) SCH (n=45) OVH (n=6) Euthyroid (n=219) SCH (n=40) OVH  (n=11)
DXA total fat (kg) 16.0±5.6 15.9±6.1 13.7±3.3 19.9±5.6 18.4±5.1 15.1±4.0
DXA muscle mass (kg) 47.6±5.0 47.3±4.8 44.9±4.8 34.7±6.5 33.3±3.0 33.0±4.6
DXA leg lean mass (kg) 15.0±2.0 14.6±1.8 13.6±2.2 10.2±1.5   9.9±1.0 10.5±1.4
CT V fat area (cm
2) 115.9±61.9 133.1±65.7 104.6±39.3 111.5±45.7 100.0±38.5   91.7±43.2
CT SC fat area (cm
2) 120.8±51.8 134.1±58.5 110.3±47.8 195.0±69.3 205.9±63.8 210.5±93.7
CT midthigh area (cm
2) 160.4±29.2 161.9±28.7 150.8±25.1 106.5±24.0 107.6±17.3 104.7±16.2
Sarcopenia, No. (%)* 63 (34.8) 15 (33.3) 3 (50.0) 17 (9.4)    9 (22.5)
‡ 0 (0.0)
Sarcopenia, No. (%)
† 69 (38.1) 18 (40.0) 3 (50.0) 108 (49.3) 26 (65.0) 1 (9.1)
Sarcopenia was defined as follows; Appendicular skeletal muscle mass (ASM) was measured by DXA. We used two definitions, which is *ASM divided by height squared (ASM/
Ht
2 in kg/m
2) and 
†ASM as a percentage of body weight (ASM/Wt). Sarcopenia was defined as <1 standard deviation below the sex-specific mean for a young reference group. 
‡P<0.05 vs. euthyroid.
SCH, subclinically hypothyroid; OVH, overtly hypothyroid; DXA, dual energy X-ray absorpt ometry; CT, computed tomography; V fat, visceral fat; SC fat, subcutaneous fat; CT 
midthigh area, CT midthigh muscle area.
Table 2. Multivariate analysis for variables associated with sarcopenia
Variables
OR (95% Confidence interval)
Male Female
For sarcopenia defined by ASM/Ht
2
   Age (yr)
   TSH (mU/L)
   PMHx of Diabetes (No vs. Yes)
   PMHx of Hpertension (No vs. Yes)
   Alcohol (No vs. Yes)
   Smoking (No vs. Yes)
   LDL-C (mg/dL)
   Knee pain (No vs. Yes)
   PAS
1.101 (1.043-1.163)
1.092 (0.664-1.796)
0.913 (0.437-1.904)
0.643 (0.310-1.333)
0.633 (0.283-1.418)
1.758 (0.791-3.907)
 1.006 (0.996-1.017)
1.621 (0.569-4.615)
1.053 (0.994-1.116)
0.985 (0.893-1.087)
2.083 (0.845-5.137)
0.726 (0.211-2.502)
0.513 (0.160-1.646)
1.012 (0.187-5.474)
2.926 (0.466-18.362)
1.007 (0.988-1.025)
0.871 (0.085-8.902)
0.956 (0.853-1.072)
For sarcopenia defined by ASM/Wt
   Age (yr)
   TSH (mU/L)
   History of Diabetes (No vs. Yes)
   History of Hypertension (No vs. Yes)
   Alcohol (No vs. Yes)
   Smoking (No vs. Yes)
   LDL-C (mg/dL)
   Knee pain (No vs. Yes)
   PAS
0.998 (0.948-1.052)
0.962 (0.592-1.563)
3.348 (1.648-6.802)
2.017 (0.969-4.199)
0.335 (0.148-0.756)
2.267 (1.019-5.046)
1.005 (0.994-1.015)
1.640 (0.565-4.760)
0.958 (0.899-1.021)
1.007 (0.951-1.066)
0.941 (0.563-1.574)
1.154 (0.585-2.276)
1.372 (0.664-2.837)
1.293 (0.463-3.615)
0.969 (0.240-3.615)
1.000 (0.989-1.010)
0.609 (0.174-2.133)
1.011 (0.958-1.067)
Covariate: age, alcohol, smoking, history of diabetes, hypertension, and acute coronary 
event, LDL-cholesterol, leg fat free mass, physical activity score, the presence of knee 
pain.
LDL-C, low density lipoprotein cholesterol; ASM, appendicular skeletal muscle mass; 
PAS, physical activity score.Moon MK, et al.  •  Subclinical Hypothyroidism and Sarcopenia in Elderly People
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of sarcopenia defined as ASM/Wt was 38.8% in men and 50% in 
women.
  When analyzed according to thyroid hormonal status, the prev-
alence of sarcopenia by both definitions did not differ between 
the euthyroid, SCH, and OVH men (Table 1). Among women, 
the prevalence also did not differ between the euthyroid and 
SCH groups when defined as ASM/Wt (49.3% vs. 65.0%); how-
ever, when defined as ASM/Ht
2, the prevalence was higher in 
SCH than in euthyroid women (22.5% vs. 9.4%).
  We performed multivariate analysis to investigate further the 
variables associated with sarcopenia. Age, the presence of dia-
betes, alcohol use, and smoking were risk factors for sarcopenia 
(Table 2). Subclinical hypothyroidism and increased TSH levels 
were not associated with sarcopenia. All the other indexes of leg 
muscle mass, muscle strength, and muscle quality were not asso-
ciated with thyroid dysfunction in both men and women (data 
not shown). Taken together, these data suggest that subclinical 
hypothyroidism has no additional harmful influence on muscle 
mass or sarcopenia in elderly subjects.
The effects of subclinical hypothyroidism on muscle 
strength and muscle quality
Table 3 shows the peak torque and total work (representing mus-
cle strength) of the dominant leg measured using an isokinetic 
dynamometer. Muscle strength measured during flexion or exten-
sion did not differ between euthyroid and SCH subjects. Mus-
cle strength showed a nonsignificant tendency to be lower in 
OVH subjects than in euthyroid and SCH subjects. Similar results 
were observed for the indexes of muscle quality (leg peak torque 
or total work divided by DXA leg lean or CT midthigh muscle 
area) in euthyroid and SCH subjects. Muscle quality by CT area 
was lower in OVH subjects than in euthyroid and SCH subjects, 
with borderline significance. When we compared these indexes 
of muscle strength and muscle quality between the right and left 
legs, the results were similar between the dominant and non-
dominant legs (data not shown).
The effects of subclinical hypothyroidism on physical 
activities or performances
To determine whether thyroid functional status was associated 
with physical performance, the presence of disability, and qual-
ity of life in these subjects, we used the PAS, ABC scale, POMA, 
and SPPB to represent physical performance, and the presence 
of knee pain and the WOMAC to evaluate the presence of dis-
ability. Quality of life was evaluated using the SF36 question-
naire. The scores on these scales did not differ between thyroid 
function groups in men and women (data not shown).
 
DISCUSSION
The number of elderly people is increasing markedly worldwide. 
Aging is associated with a decrease in lean body mass and in-
crease in fat mass (1). Sarcopenia affects muscle mass, strength, 
and quality, and these changes are associated with physical dis-
ability, morbidity, and mortality. Sarcopenia is of considerable 
clinical importance in elderly people.
  Sarcopenic women have 3.6-times higher rates of disability 
and sarcopenic men have 4.1-times higher rates compared with 
people with normal muscle mass (4). The causes of sarcopenia 
are diverse. Neuronal loss and changes in hormones such as sex 
hormones, growth hormone, and insulin adversely affect mus-
cle mass. Diabetes mellitus is associated with severe muscle wast-
Table 3. Muscle strength and quality of dominant leg according to the thyroid functional status
Specific torque 
   measure
Male Female
Euthyroid (n=207) SCH (n=48) OVH (n=6) P Euthyroid (n=204) SCH (n=43) OVH (n=7) P
Peak torque (Nm)
   Extension
   Flexion
  80.7±29.8
  39.7±16.7
  78.0±26.9
  40.1±16.4
  81.1±26.3
  32.1±16.4
0.838
0.650
  50.1±18.1
  24.1±10.2
  51.0±15.4
23.6±8.6
  38.8±20.1
  19.7±12.7
0.232
0.556
Total work
   Extension
   Flexion
  349.9±132.0
196.5±98.8
  331.5±119.3
191.9±89.2
  378.1±120.5
  199.8±117.8
0.568
0.954
216.1±84.6
118.3±61.4
222.6±68.4
116.5±57.1
167.3±93.3
  87.7±60.8
0.259
0.424
Peak torque/DXA leg lean mass (Nm/kg)
   Extension
   Flexion
   5.61±1.66
  2.80±0.91
  5.43±1.50
  2.74±0.94
  5.97±1.83
  2.17±0.76
0.686
0.385
  5.16±1.63
  2.48±0.98
  5.26±1.45
  2.45±0.82
  5.17±1.45
  2.51±1.23
0.943
0.984
Total work/ DXA leg lean mass
   Extension
   Flexion
24.5±7.3
13.9±5.6
23.1±6.7
13.3±5.3
27.9±8.6
14.5±9.1
0.255
0.782
22.3±7.5
12.2±5.5
23.1±6.3
12.0±5.5
21.8±6.7
11.4±5.5
0.817
0.946
Peak torque/ CT area (Nm/cm
2)
   Extension
   Flexion
  0.49±0.17
  0.24±0.10
  0.48±0.16
  0.26±0.10
  0.54±0.09
  0.22±0.11
0.810
0.615
  0.45±0.16
  0.21±0.09
  0.50±0.15
  0.23±0.10
  0.33±0.19
  0.17±0.10
0.052
0.320
Total work/ CT area
   Extension
   Flexion
  2.13±0.74
  1.17±0.57
  2.03±0.68
  1.22±0.50
  2.51±0.44
   1.11±0.69
0.486
0.843
  1.95±0.77
   1.02±0.53
  2.23±0.76
  1.11±0.62
  1.46±0.87
  0.73±0.50
0.079
0.330
SCH, subclinically hypothyroid; OVH, overtly hypothyroid; DXA, dual energy X-ray absorptiometry; CT, computed tomography; CT area, CT midthigh muscle area.Moon MK, et al.  •  Subclinical Hypothyroidism and Sarcopenia in Elderly People
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ing, and the risk of insulin resistance increases with aging, fat 
mass, and physical inactivity (24). Baumgartner et al. (25) re-
ported that muscle mass is significantly associated with heart 
disease in older men and with total fat mass in older women.
  The prevalence of thyroid dysfunction, especially subclinical 
hypothyroidism, is increasing because of the increase in routine 
screening of thyroid function. The prevalence of subclinical hypo-
thyroidism also increases with age (13) and now affects 5–10% 
of the general population and up to 20% of older women (26, 27). 
Skeletal muscle is a target organ for thyroid hormones (9, 10). 
Both hypothyroidism and hyperthyroidism can affect limb mus-
cle mass and muscle strength. Treatment of hypothyroidism with 
thyroid hormone improves skeletal muscle function (28). In SCH 
and OVH subjects, knee flexor and extensor muscle strength and 
midthigh muscle cross-sectional area are significantly lower than 
the values in euthyroid subjects (11). However, the association 
between muscle mass or muscle strength and subclinical hypo-
thyroidism has not been reported until now. We evaluated these 
associations for the first time, and we conclude that muscle mass, 
the prevalence of sarcopenia, muscle strength, and muscle qual-
ity are not affected by mild thyroid dysfunction in elderly people.
  The female SCH subjects in our study had a higher prevalence 
of sarcopenia defined as ASM/Ht
2 than did the euthyroid sub-
jects (22.5% vs. 9.4%). To rule out the effects of other risk factors 
for sarcopenia, we excluded subjects with history of stroke be-
cause it is the most well-known risk factor associated with loss 
of muscle mass and muscle function (29, 30). We also adjusted 
for other covariates, such as blood glucose and lipid levels, in 
the multivariate analysis and found no effect of subclinical hy-
pothyroidism on muscle function and sarcopenia. However, in 
the correlation analysis (data not shown), total muscle mass, and 
muscle areas measured by CT correlated more strongly with ASM/ 
Ht
2 (muscle mass, r=0.356, P<0.001; midthigh CT muscle area, 
r=0.330, P<0.001) than with ASM/Wt (muscle mass, r=–0.051, 
P= 0.489; midthigh CT muscle area, r=0.108, P=0.229). Thus, al-
though the statistical significance disappeared after multivari-
ate analysis, the possible relationship between sarcopenia and 
SCH, at least in elderly women, cannot be ruled out completely.
  Muscle mass, strength, and quality did not differ between 
euthyroid, SCH, and OVH subjects within either sex. Indices of 
physical performance, disability, and quality of life did not dif-
fer between SCH and euthyroid subjects. Even after the multi-
variate analysis including age, diabetes and hypertension, his-
tory of acute coronary event, alcohol, smoking, presence of pain, 
physical activity score and lipid profile, TSH level was not asso-
ciated with muscle mass, muscle strength, or muscle quality. We 
found no definite evidence of an association between subclini-
cal hypothyroidism and muscle mass or function in this group 
of older people study.
  Our data showing no relationship between hypothyroidism 
and anthropometric and laboratory characteristics, muscle mass, 
strength, and quality contrast with other reports (11, 28). This 
difference may relate to the small number of enrolled OVH sub-
jects (n=23) and even smaller numbers after dividing the group 
by sex (7 men, 16 women). However, muscle strength and qual-
ity showed a borderline significant tendency to be lower in the 
OVH group, suggesting that hypothyroidism affects muscle func-
tion in elderly people. It is also possible that, in all elderly sub-
jects, the effects of aging itself are so large that they mask any 
adverse effects on muscle caused by overt or subclinical hypo-
thyroidism.
  In conclusion, subclinical hypothyroidism has little influences 
on muscle mass, strength, and quality, and may not be associated 
with sarcopenia in elderly people.
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